ETIDIOH - NEW

  {By Diliff - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=1385555 } Following the detection of HPAI H5N1 in a greylag goose found dead near the lake Biel on 4 November 2025, an infected area of 3 km around the three lakes in vicinity of the site of detection has been put in place. Within this area, measures of increased disease awareness, biosecurity and notification obligations have to be followed by poultry owners. A wild Greylag Goose found dead in Bern Region. Source: WOAH,  https://wahis.woah.org/#/in-review/6985 ____

  {England} Mixed commercial premises with 32.7k ducks and 11.6k broilers. Samples taken were positive for HPAI H5N1. Birds presented clinical signs of AI prior to testing. Source: WOAH,  https://wahis.woah.org/#/in-review/6987 ____

  Abstract Samples collected from two avian influenza outbreaks in Bagmati Province in central Nepal between January and March 2023 were positive for H5N1 . Full genomes were generated for both viruses, which revealed that one of the viruses was very similar to clade 2.3.4.4b H5N1 identified in Bangladesh in 2021/2022. The second virus was a reassortant H5N1 virus consisting of four genes (HA, NA, NP, and M) originating from a clade 2.3.2.1a H5N1 and the remaining four genes (NS, PB1, PB2, and PA) originating from a 2.3.4.4b H5N1 . Notably, this second virus had a high identity with 2.3.2.1a clade viruses identified in humans and cats in India in 2024–2025. These are the first full genome sequences of H5N1 avian influenza viruses from Nepal and given the recent human infections by 2.3.2.1a H5N1 viruses in the region, these data will be of interest to both public health and veterinary authorities. Source: Viruses,  https://www.mdpi.com/1999-4915/17/11/1481 ____

  Abstract Mucosal influenza vaccines may provide improved protection against infection and transmission , but their development is hindered by absence of immune correlates of protection . Here, we report a randomized, controlled phase I trial of a recombinant influenza A/H5 (A/Indonesia/05/2005, clade 2.1) hemagglutinin vaccine formulated with a nanoemulsion adjuvant (W805EC). The vaccine is administered intranasally in two doses 28 days apart at three antigen levels. Controls receive unadjuvanted H5 or placebo. Six months later, participants receive an intramuscular boost with unadjuvanted inactivated A/H5N1 (A/Vietnam/1203/2004, clade 1) vaccine. Primary outcomes are solicited and unsolicited adverse events (AEs), laboratory safety abnormalities, medically-attended AEs, potential immune-mediated conditions, new-onset chronic conditions, and serious AEs. All vaccines are well tolerated. After the intranasal series, hemagglutination inhibition and microneutralization responses are...

  Situation at a glance Between 20 September and 30 October 2025, a total of 404 confirmed human cases of Rift Valley fever (RVF), including 42 deaths , were reported by national health authorities in two West African countries : Mauritania and Senegal .  RVF is a zoonotic disease , which mainly affects animals, but can also infect humans.  The majority of human infections result from contact with the blood or organs of infected animals, but human infections have also resulted from the bites of infected mosquitoes .  To date, no human-to-human transmission of RVF has been documented.  While RVF often leads to severe illness in animals, its impact in humans varies, ranging from mild flu-like symptoms to severe hemorrhagic fever that can be fatal .  RVF is endemic in both countries, where recurrent outbreaks have been previously reported in both livestock and humans.  The risk of further spread remains high , especially with environmental conditions favo...

  Abstract Background No vaccine is currently available for Lassa fever, a viral hemorrhagic disease that is estimated to cause thousands of deaths each year in western Africa . A replication-competent recombinant vesicular stomatitis virus–vectored vaccine encoding a Lassa virus (LASV) glycoprotein complex, rVSVΔG-LASV-GPC, has been developed, but data on its safety and immunogenicity are limited. Methods In this phase 1, double-blind trial conducted in the United States and Liberia, we randomly assigned healthy adults (18 to 50 years of age) to receive rVSVΔG-LASV-GPC or placebo intramuscularly . Participants received a single vaccine dose of 2×104 plaque-forming units (PFU), 2×105 PFU, 2×106 PFU, or 2×107 PFU or placebo or received two vaccine doses of 2×107 PFU or placebo, within a window of 6 to 20 weeks. The side-effect profile was assessed according to the incidence of solicited and unsolicited adverse events (primary end point). Because Lassa fever can cause sensorineural h...